MOUNTAIN VIEW, California, February 10 /PRNewswire/ -- Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
Leading EU centers began initial clinical evaluation of the Trevo System following receipt of CE Mark in late 2009. Numerous cases have been performed and early clinical feedback continues to be positive.
Maria Sainz, President and CEO of Concentric Medical, said, I am thrilled Concentric has received these approvals and that physician feedback on our initial cases has been so encouraging. These approvals combined with the positive feedback will allow us to introduce the Trevo System to customers in Europe and Canada in the near future.
About Concentric Medical
Concentric Medical is located in Mountain View, California and is the global leader in the endovascular treatment of acute ischemic stroke. The company manufactures and markets solutions for ischemic stroke: minimally invasive devices that are delivered into the brain to restore blood flow by removing blood clots that cause ischemic stroke. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies. For more information about Concentric Medical, please visit http://www.concentric-medical.com.
About the Trevo System
The Trevo System is an innovative, high-performing, easy-to-use thrombus retrieval system. The main component of the Trevo System is a stentriever(TM), a new generation of retrieval device that removes clots that cause stroke.
About Acute Ischemic Stroke
Stroke is the third leading cause of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain. In 2004 the FDA cleared Concentric Medical's Merci Retriever(R) for use in patients who are ineligible for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device created a departure from the historic method of caring for stroke patients and offered physicians and patients a long-awaited option for stroke intervention.
Media Contact: Scott Meggs, Corporate Counsel +1-650-938-2100 strokeinfo@concentric-medical.com
SOURCE: Concentric Medical, Inc.
CONTACT: Scott Meggs, Corporate Counsel of Concentric Medical,+1-650-938-2100, strokeinfo@concentric-medical.com
Comments